A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Clinical trial NCT06018428 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06018428
- Sponsor
- Q32 Bio Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-12
- Primary completion
- 2026-06-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.